Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Keith Dredge

Showing results (21-30 of 40) with videos related to

Pageof 4
Sort By:
Blood|July 5, 2012
Heparan sulfate, an endogenous TLR4 agonist, promotes acute GVHD after allogeneic stem cell transplantationTodd V Brennan, Liwen Lin, Xiaopei Huang, et al.
Molecular Cancer Therapeutics|July 19, 2017
Inhibition of Heparanase in Pediatric Brain Tumor Cells Attenuates their Proliferation, Invasive Capacity, and <i>In Vivo</i> Tumor GrowthArgyris Spyrou, Soumi Kundu, Lulu Haseeb, et al.
Seminars in Thrombosis and Hemostasis|July 17, 2007
PI-88 and novel heparan sulfate mimetics inhibit angiogenesisVito Ferro, Keith Dredge, Ligong Liu, et al.
Scientific Reports|February 8, 2017
Loss of HSulf-1: The Missing Link between Autophagy and Lipid Droplets in Ovarian CancerDebarshi Roy, Susmita Mondal, Ashwani Khurana, et al.
Journal for Immunotherapy of Cancer|June 15, 2018
Immunomodulatory activities of pixatimod: emerging nonclinical and clinical data, and its potential utility in combination with PD-1 inhibitorsEdward Hammond, Nicole M Haynes, Carleen Cullinane, et al.
British Journal of Cancer|March 14, 2018
A Phase I study of the novel immunomodulatory agent PG545 (pixatimod) in subjects with advanced solid tumoursKeith Dredge, Todd V Brennan, Edward Hammond, et al.
Oncotarget|October 15, 2019
Correction: The heparan sulfate mimetic PG545 interferes with Wnt/β-catenin signaling and significantly suppresses pancreatic tumorigenesis alone and in combination with gemcitabineDeok-Beom Jung, Miyong Yun, Eun-Ok Kim, et al.
Oncotarget|February 12, 2015
The heparan sulfate mimetic PG545 interferes with Wnt/β-catenin signaling and significantly suppresses pancreatic tumorigenesis alone and in combination with gemcitabineDeok-Beom Jung, Miyong Yun, Eun-Ok Kim, et al.
Cancer Research|February 5, 2003
A novel subclass of thalidomide analogue with anti-solid tumor activity in which caspase-dependent apoptosis is associated with altered expression of bcl-2 family proteinsJ Blake Marriott, Ian A Clarke, Anna Czajka, et al.
Microvascular Research|March 31, 2005
Orally administered lenalidomide (CC-5013) is anti-angiogenic in vivo and inhibits endothelial cell migration and Akt phosphorylation in vitroKeith Dredge, Rebecca Horsfall, Simon P Robinson, et al.
Pageof 4

Showing results (21-30 of 40) with videos related to

Sort By:
Pageof 4
Blood|July 5, 2012
Heparan sulfate, an endogenous TLR4 agonist, promotes acute GVHD after allogeneic stem cell transplantationTodd V Brennan, Liwen Lin, Xiaopei Huang, et al.
Molecular Cancer Therapeutics|July 19, 2017
Inhibition of Heparanase in Pediatric Brain Tumor Cells Attenuates their Proliferation, Invasive Capacity, and <i>In Vivo</i> Tumor GrowthArgyris Spyrou, Soumi Kundu, Lulu Haseeb, et al.
Seminars in Thrombosis and Hemostasis|July 17, 2007
PI-88 and novel heparan sulfate mimetics inhibit angiogenesisVito Ferro, Keith Dredge, Ligong Liu, et al.
Scientific Reports|February 8, 2017
Loss of HSulf-1: The Missing Link between Autophagy and Lipid Droplets in Ovarian CancerDebarshi Roy, Susmita Mondal, Ashwani Khurana, et al.
Journal for Immunotherapy of Cancer|June 15, 2018
Immunomodulatory activities of pixatimod: emerging nonclinical and clinical data, and its potential utility in combination with PD-1 inhibitorsEdward Hammond, Nicole M Haynes, Carleen Cullinane, et al.
British Journal of Cancer|March 14, 2018
A Phase I study of the novel immunomodulatory agent PG545 (pixatimod) in subjects with advanced solid tumoursKeith Dredge, Todd V Brennan, Edward Hammond, et al.
Oncotarget|October 15, 2019
Correction: The heparan sulfate mimetic PG545 interferes with Wnt/β-catenin signaling and significantly suppresses pancreatic tumorigenesis alone and in combination with gemcitabineDeok-Beom Jung, Miyong Yun, Eun-Ok Kim, et al.
Oncotarget|February 12, 2015
The heparan sulfate mimetic PG545 interferes with Wnt/β-catenin signaling and significantly suppresses pancreatic tumorigenesis alone and in combination with gemcitabineDeok-Beom Jung, Miyong Yun, Eun-Ok Kim, et al.
Cancer Research|February 5, 2003
A novel subclass of thalidomide analogue with anti-solid tumor activity in which caspase-dependent apoptosis is associated with altered expression of bcl-2 family proteinsJ Blake Marriott, Ian A Clarke, Anna Czajka, et al.
Microvascular Research|March 31, 2005
Orally administered lenalidomide (CC-5013) is anti-angiogenic in vivo and inhibits endothelial cell migration and Akt phosphorylation in vitroKeith Dredge, Rebecca Horsfall, Simon P Robinson, et al.
Pageof 4